Bruker Corp Stock Price, News & Analysis

Gauss Fusion GmbH, established in 2022, aims to develop a European GW-class fusion power plant by 2045. The venture secured €8 million in pre-seed financing in February 2023 and emphasizes close collaboration with European research institutions, including the Max Planck Institute. Gauss Fusion seeks to accelerate fusion energy development through a public-private partnership model, addressing the growing energy demand while supporting a net-zero society. The initiative has garnered political attention following breakthroughs in fusion energy, with expectations of industrial partnerships to enhance its goals.

Bruker Corporation (NASDAQ: BRKR) announced that Executive Vice President and CFO Gerald Herman will present at two upcoming investor conferences. The first is the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York City on March 2, 2023, at 9:30 a.m. ET. The second is the Cowen 43rd Annual Health Care Conference in Boston, MA, scheduled for March 6, 2023, at 2:10 p.m. ET. The presentations will be available via live webcasts on the Company’s Investor Relations website, with replays accessible for 90 days following the events.

Bruker Corporation (Nasdaq: BRKR) has declared a quarterly cash dividend of $0.05 per share, set to be paid on March 17, 2023. Stockholders on record as of March 1, 2023 will receive this dividend. The company focuses on providing high-performance scientific instruments and analytical solutions, aiding in breakthroughs in life-science research and diagnostics. This dividend reflects Bruker’s commitment to returning value to shareholders while continuing to invest in innovation and customer success.

Bruker Corporation reported Q4 2022 revenues of $708.4 million, up 3.6% year-over-year, with 8.9% organic growth. GAAP EPS was $0.66, while non-GAAP EPS rose 25.4% to $0.74. For FY 2022, revenues reached $2.531 billion, marking an increase of 4.7%, and 10.2% organic growth. GAAP EPS for FY 2022 was $1.99 with a non-GAAP EPS of $2.34, up 11.4%. Looking ahead, Bruker projects FY 2023 revenues of $2.81 to $2.86 billion with non-GAAP EPS guidance of $2.52 to $2.57, indicating 8% to 10% growth.

Bruker Corporation has successfully installed two novel, compact 1.0 GHz NMR systems for structural and molecular biology applications at RIKEN in Japan and the University of Barcelona in Spain, ahead of schedule in late 2022. These Ascend Evo 1.0 GHz NMR systems operate at 4.2 Kelvin and consume approximately 65% less liquid helium compared to previous models. The compact design eases site installation and is expected to enhance research in biomolecular dynamics. The installations are already generating valuable scientific data, contributing to advancements in life sciences and clinical research.

Bruker Corporation (Nasdaq: BRKR) will report its fourth quarter and fiscal year 2022 financial results before market opening on February 9, 2023. A conference call and webcast will follow at 8:30 a.m. EST to discuss these results and current business trends. Investors can listen to the webcast at Bruker's Investor Relations website. Pre-registration for the call is available to streamline access. A replay of the conference call will be accessible from March 9, 2023, along with a slide presentation available shortly before the webcast begins.

Bruker Corporation (Nasdaq: BRKR) announced its acquisition of ACQUIFER Imaging GmbH, enhancing its bioimaging solutions. This acquisition includes ACQUIFER's HIVE data management system, which supports high-performance computing and big-data storage for microscopy applications. Additionally, the IM04 Imaging Instrument expands Bruker's portfolio into high-content screening. The financial details of the deal were not disclosed, but it is expected to enhance Bruker's capabilities in life science research, particularly in organoid and stem cell studies.

Bruker has announced a strategic partnership with Biognosys, acquiring a majority stake to enhance access to Biognosys' CRO services and Spectronaut® software for proteomics research. The partnership aims to support drug discovery, biomarker development, and clinical trials, with plans to establish a new advanced proteomics facility in the US. The collaboration leverages Bruker's technology alongside Biognosys' expertise, promising improved proteomics capabilities and expanded services for their biomarker and biopharma clientele.